Amalia Douma

Dr. Amalia Douma


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Panagiotis ChatzistavridisPanagiotis Chatzistavridis
Panagiotis Chatzistavridis
AGAnna Gkiouliava
Anna Gkiouliava
ADAmalia Douma
Amalia Douma
Kassiani TheodorakiKassiani Theodoraki
Kassiani Theodoraki
Background/Objectives: The Eleveld pharmacokinetic–pharmacodynamic (PK-PD) model is among the most extensively validated general-purpose models for propofol target-controlled infusion (TCI). It includes a binary covariate for concomitant drug administration, commonly labelled as opioid use, which reduces elimination clearance (CL) and the volume of the second peripheral compartment (V3) in an age-dependent manner. This works well for conventional opioid-based anaesthesia but is less clear for multimodal, opioid-sparing regimens built around ketamine, magnesium sulfate, dexmedetomidine and intravenous lidocaine. This review discusses how these four non-opioid adjuvants may interact with Eleveld-based propofol TCI dosing. Methods: We conducted a structured, non-systematic literature search of PubMed/MEDLINE, the Cochrane Library and the MDPI full-text index between May and early August 2026, combining terms for the Eleveld model and propofol TCI with terms for each adjuvant and for pharmacodynamic endpoints (EC50, Ce50, bispectral index, propofol requirement). Studies without a propofol-specific endpoint were excluded from the adjuvant-effect analysis. Results: Dexmedetomidine reduced the propofol concentration required for defined clinical and electroencephalographic endpoints. Magnesium sulfate reduced propofol dose requirements to a lesser extent, although concentration–response data are lacking. Ketamine’s interaction with propofol was additive rather than synergistic, and its effect on the bispectral index was dose-dependent. Lidocaine reduced propofol requirements mainly during surgical stimulation, a context-dependent effect distinct from a fixed hypnotic potency. Conclusions: The Eleveld model remains the best-validated general-purpose tool for propofol TCI, and its concomitant-drug covariate is a pragmatic, data-driven solution to a real gap in its source data. Clinicians should anticipate reduced propofol requirements with dexmedetomidine and, to a lesser extent, magnesium, interpret the processed-EEG response to ketamine cautiously, and expect lidocaine’s sparing effect mainly under stimulation, while titrating to clinical and electroencephalographic endpoints. Dedicated covariates for these agents, informed by prospective validation in opioid-free regimens, represent a logical next step in the model’s development.

2 September 2019
Verified
Conference Paper
Closed access
ADAmalia Douma
Amalia Douma
PPPanayota Priftaki
Panayota Priftaki
AAAntonia Andreeva
Antonia Andreeva
AMAntigoni Malefaki
Antigoni Malefaki
ADAntonia Dimakopoulou
Antonia Dimakopoulou

23 October 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
Panagiotis ChatzistavridisPanagiotis Chatzistavridis
Panagiotis Chatzistavridis
AGAnna Gkiouliava
Anna Gkiouliava
ADAmalia Douma
Amalia Douma
Kassiani TheodorakiKassiani Theodoraki
Kassiani Theodoraki
Background/Objectives: Obesity alters propofol pharmacokinetics, creating bidirectional safety concerns during Target-Controlled Infusion (TCI). The 5th National Audit Project reported that patients with obesity were over-represented among cases of accidental awareness, and that awareness was more frequent when neuromuscular blockade was used. Methods: We examined the literature on the mechanisms and clinical evidence underlying relative overdosing, underdosing, awareness, and postoperative respiratory risk in patients with obesity receiving propofol anesthesia. Results: Total body-weight dosing may produce an excessive initial concentration, because the central compartment expands less than body weight, contributing to hemodynamic instability at induction. Conversely, inappropriate dose reduction based on lean or ideal body weight may result in inadequate anesthetic depth. Risk reduction requires the best-validated pharmacokinetic model or weight-adjustment method available, stepwise titration of the target concentration, processed electroencephalographic monitoring when total intravenous anesthesia is combined with neuromuscular blockade, quantitative neuromuscular monitoring, delivery-system checks, and vigilant postoperative respiratory monitoring. Closed-loop delivery may improve control of anesthetic depth, but a reduction in serious adverse events has not been demonstrated. Conclusions: Evidence remains limited at the upper extremes of body mass index; model predictions and fixed weight scalars should be interpreted cautiously, and dosing should be individualized using measured pharmacodynamic endpoints.

27 October 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
Panagiotis ChatzistavridisPanagiotis Chatzistavridis
Panagiotis Chatzistavridis
MNMaria Ntalouka
Maria Ntalouka
ADAmalia Douma
Amalia Douma
Kassiani TheodorakiKassiani Theodoraki
Kassiani Theodoraki
Background/Objectives: Nutritional depletion and systemic inflammation are common in patients living with obesity undergoing metabolic bariatric surgery (MBS) and may influence the risk of early postoperative complications. Composite indices derived from routine blood tests—combining markers of protein/immune reserve and inflammatory burden—offer an inexpensive means of preoperative risk stratification, but their comparative performance in MBS has not been well defined. The primary objective is to compare the prognostic performance of seven preoperative indices for early postoperative complications after MBS; the secondary objective is to estimate and rank the incremental prognostic value of each index over baseline clinical risk factors. Methods: This protocol describes a single-centre retrospective cohort study of approximately 700 consecutive adults who underwent sleeve gastrectomy, one-anastomosis gastric bypass, Roux-en-Y gastric bypass, single-anastomosis duodeno-ileal bypass with sleeve gastrectomy or single-anastomosis sleeve-ileal bypass, including revisional procedures, between 1 January 2023 and 28 June 2026; data extraction will begin only after submission of this protocol. The Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), C-reactive protein-to-Albumin Ratio (CAR) and Glucose-to-Lymphocyte Ratio (GLR) will be calculated from complete blood count, albumin, C-reactive protein and fasting glucose values. The last preoperative sample is the exposure; early postoperative values (postoperative days 1–3) will be examined in a separate exploratory landmark analysis. The primary outcome is any complication of Clavien–Dindo grade II or higher within 30 days of surgery; readmission within 30 days of surgery and prolonged hospital stay will be analysed as secondary healthcare-utilisation outcomes. The indices will be compared by their optimism-corrected incremental discrimination over a baseline clinical model, using penalised logistic regression with bootstrap internal validation and calibration assessment. Conclusions: This protocol outlines a pragmatic approach to comparing seven low-cost, routinely available nutritional–inflammatory and inflammatory indices for risk stratification before MBS. Indices showing promising performance will require external, ideally multicentre, validation before they can be considered for clinical decision making.